PMD Psychemedics Corp.

Psychemedics Recognized as a Top 10 Employee Health Testing Services Provider

Psychemedics Recognized as a Top 10 Employee Health Testing Services Provider

Dallas, TX, March 21, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in drug testing using hair analysis, is proud to announce its recognition as one of the Top 10 Employee Health Testing Services Providers for 2024 by ManageHR. This prestigious accolade highlights Psychemedics’ commitment to excellence and innovation in the field of employee health testing.

ManageHR’s annual list recognizes companies that excel in providing cutting-edge solutions and services for employee health testing. Psychemedics was selected for its exceptional performance, industry leadership, and dedication to delivering reliable and accurate testing services.

“We are honored to be recognized as one of the Top 10 Employee Health Testing Services Providers,” said Brian Hullinger, Chief Executive Officer and President of Psychemedics Corporation. “This achievement is a testament to our unwavering commitment to providing high-quality, innovative solutions for drug testing.”

Psychemedics’ patented hair analysis technology offers a non-invasive and highly accurate method for detecting drug use over an extended period, providing employers with valuable insights into their employees’ health and well-being. With over 30 years of experience, Psychemedics has helped thousands of companies worldwide maintain safe and drug-free workplaces.

For more information about Psychemedics Corporation and its innovative hair testing solutions, please visit.

About Psychemedics 

Psychemedics Corporation (NASDAQ: PMD) is a leading global provider of innovative hair testing for drugs of abuse. With over 30 years of experience, Psychemedics has pioneered the science of hair testing and provides clients with the most accurate and reliable hair drug test results in the industry. The company's patented technology is used by thousands of companies worldwide to screen applicants and employees for drug use, helping to create safer and more productive workplaces.

Investor Relations:

Phone: 978-206-8220

Email:  



EN
21/03/2024

Underlying

PMDPsychemedics Corp.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Psychemedics Corp.

 PRESS RELEASE
Free
PMD Psychemedics Co...

Psychemedics Corporation Reports 2023 Financial Results

Psychemedics Corporation Reports 2023 Financial Results DALLAS, March 28, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, announced today financial results for the year ended December 31, 2023. “2023 proved to be another challenging year due to the negative impact of major economic forces. The labor shortage continues and remains unprecedented in its severity and duration, having an adverse impact on our clients. Despite these challenges, my confidence in our potential continues to increase. As cost reducti...

March 28, 2024 1 EN
 PRESS RELEASE
Free
PMD Psychemedics Co...

Psychemedics Recognized as a Top 10 Employee Health Testing Services P...

Psychemedics Recognized as a Top 10 Employee Health Testing Services Provider Dallas, TX, March 21, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in drug testing using hair analysis, is proud to announce its recognition as one of the Top 10 Employee Health Testing Services Providers for 2024 by ManageHR. This prestigious accolade highlights Psychemedics’ commitment to excellence and innovation in the field of employee health testing. ManageHR’s annual list recognizes companies that excel in providing cutting-edge solutions and services for employee heal...

March 21, 2024 1 EN
 PRESS RELEASE
Free
PMD Psychemedics Co...

Psychemedics Corporation Announces Relocation of Headquarters to Dalla...

Psychemedics Corporation Announces Relocation of Headquarters to Dallas, Texas ACTON, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair testing for drugs of abuse, proudly announces the relocation of its corporate headquarters from Acton, Massachusetts, to Dallas, Texas, while reaffirming its unwavering dedication to delivering exceptional service and maintaining the highest standards in hair drug testing. The move to Dallas underscores Psychemedics’ commitment to expanding operations, fostering innovation, and better serving its diverse cliente...

January 2, 2024 1 EN
 PRESS RELEASE
Free
PMD Psychemedics Co...

Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance

Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance ACTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for substance abuse, proudly announces the appointment of Daniella Mehalik as its new Vice President - Finance. In her new role, Ms. Mehalik will assume responsibility for directing and managing all financial activities at Psychemedics, including comprehensive oversight of external reporting and internal analysis. Reporting directly to CEO and President Brian Hullinger, she will play a pivotal role in st...

November 27, 2023 1 EN
 PRESS RELEASE
Free
PMD Psychemedics Co...

Psychemedics Corporation Reports Third Quarter 2023 Financial Results

Psychemedics Corporation Reports Third Quarter 2023 Financial Results ACTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ended September 30, 2023. The Company’s revenue for the quarter ended September 30, 2023, was $5.7 million versus $6.5 million for the quarter ended September 30, 2022, a decrease of 12%. Net loss for the quarter ended September 30, 2023, was $(2.1 million) or $(0.36) per diluted share, versus net loss of $(97,000) or $(0.0...

November 9, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch